The following table summarizes the top 50 companies in Pharmaprojects in the January 2007 update, using data collected on 14th December 2006. It lists companies in descending order by total number of active Research and Development (R&D) projects (excluding suspended products). Each company’s total R&D products are separated into the number of drugs originating from its own research and the number of drugs it has licensed in. The table also lists subtotals at 10 place intervals. The percentage values represent the number of drugs in R&D as a proportion of the total number of R&D projects listed in Pharmaprojects in January 2007.
| position |
No of |
No of |
No under |
| January 2007 |
R&D drugs |
own drugs |
licence |
| |
|
|
|
| 1 |
GlaxoSmithKline* |
193 |
124 |
69 |
| 2 |
Sanofi-Aventis* |
164 |
108 |
56 |
| 3 |
Novartis* |
157 |
88 |
69 |
| 4 |
Hoffmann-La Roche* |
139 |
69 |
70 |
| 5 |
Merck& Co* |
132 |
93 |
39 |
| 6 |
AstraZeneca* |
115 |
89 |
26 |
| 7 |
Pfizer* |
108 |
71 |
37 |
| 8 |
Wyeth* |
105 |
76 |
29 |
| 9 |
Johnson& Johnson |
92 |
43 |
49 |
| 10 |
Daiichi Sankyo |
82 |
53 |
29 |
| Subtotal : top10 |
1287(18%) |
814(11.3%) |
437(20.1%) |
| |
|
|
|
|
| 11 |
Bayer* |
77 |
44 |
33 |
| 12 |
Gardant Pharmaceuticals |
76 |
70 |
6 |
| 13 |
Bristol-Myers Squibb* |
72 |
43 |
29 |
| 14 |
Astellas |
71 |
41 |
30 |
| 15 |
Amgen |
65 |
46 |
19 |
| 16 |
Eli Lilly* |
63 |
38 |
25 |
| 17 |
Abbott* |
58 |
37 |
21 |
| 18 |
Akzo Nobel* |
54 |
42 |
12 |
| 19 |
Takeda |
53 |
19 |
34 |
| 20 |
Genzyme |
48 |
31 |
17 |
| Subtotal : top20 |
1924(27%) |
1225(17%) |
699 (29.7%) |
| |
|
|
|
|
| 21 |
Solvay* |
48 |
30 |
18 |
| 22 |
Schering-Plough |
47 |
21 |
26 |
| 23 |
Eisai |
42 |
27 |
15 |
| 24 |
Medarex |
41 |
32 |
9 |
| 25 |
Dainippon Sumitomo P |
40 |
26 |
14 |
| 26 |
Serono |
38 |
13 |
25 |
| 27 |
Crucell |
34 |
29 |
5 |
| 28 |
BTG |
34 |
27 |
7 |
| 29 |
Genentech |
34 |
15 |
19 |
| 30 |
Shire |
34 |
17 |
17 |
| Subtotal : top30 |
2316(32.6%) |
1462(20.3%) |
854(36.3%) |
| |
|
|
|
|
31 |
Cephalon |
33 |
23 |
10 |
32 |
Mitsubishi Pharma |
29 |
23 |
6 |
33 |
Elan |
28 |
13 |
15 |
34 |
Biogen Idec |
28 |
15 |
13 |
35? |
Novo Nordisk* |
28 |
13 |
15 |
36 |
MedImmune |
27 |
15 |
12 |
37 |
Ipsen |
26 |
17 |
9 |
38 |
Teva |
25 |
13 |
12 |
39 |
Boehringer Ingelheim* |
24 |
15 |
9 |
40 |
Allergan |
23 |
14 |
9 |
| Subtotal : top 40 |
2587(36.3%) |
1623(22.5%) |
964(41%) |
| |
|
|
|
|
41 |
Gilead Sciences |
23 |
17 |
6 |
42 |
Servier |
23 |
17 |
6 |
43 |
UCB |
23 |
14 |
9 |
44 |
Debiopharm |
22 |
14 |
8 |
45 |
AEterna Zentaris |
22 |
22 |
0 |
46 |
Kirin Brewery |
22 |
12 |
10 |
47 |
LG Life Sciences |
22 |
14 |
8 |
48 |
Amphora |
21 |
21 |
0 |
49 |
Vernalis |
21 |
21 |
0 |
50 |
Exelixis |
20 |
14 |
6 |
| Subtotal : top50 |
2806(39.3%) |
1789(24.8%) |
1017(43.3%) |
| |
|
|
|
|
|
首 页
